Home › Research › Treatments
Investigating The Neuroprotective Role of Curcumin in Alzheimer's Disease Models
Soumyajit Panda, Akash Kumar, Sapna Rani, Sowvik Bag. Journal of Pharmacology Genetics and Molecular Biology, 2025-08-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer disease (AD) is a pathological worsening process of neurodegenerative disease characterised by impaired thinking, memory and behavioural problems, which have a considerable health impact worldwide. There is no disease-altering treatment at the present day that can help limit the progression of the disease, which is why there is the strong necessity to develop a disease-modifying medication. Natural therapeutic explores in curcumin A polyphenolic compound, curcumin found in Curcuma longa (turmeric) has gained a lot of interests to potential natural therapeutic agent because of its powerful antioxidant, anti-inflammatory, anti-amyloid and chelation towards metals. This review provides a comprehensive study on the neuroprotective effects of curcumin in the case of Alzheimer disease, its biochemical and pharmacological profile in its application regarding unique chemical content, bioactive compounds of curcumin, and pharmacokinetic constraints, like poor bioavailability. In vitro studies at the preclinical level show that curcumin can limit neurotoxicity caused by amyloid beta, prevent the formation of aggregates, and limit oxidative and inflammatory injuries and in vivo-based rodent trials report both cognitive and behavioural enhancements as well as the decrease of amyloid plaque and hyperphosphorylation of tau proteins. However, several limitations like low bioavailability, absence of large-scale, clinical trials, and insufficiency of long range safety make clinical implementation poor. The future study is needed to create a nano formulation, which will improve its bioavailability and combination therapies, which will produce a synergistic neuroprotective effect. In general, curcumin has a large potential as effective safe multi-targeted therapy against Alzheimer disease and its relevance should be further investigated due to conducting well-conducted human trials that may determine its effectiveness.
What this study adds
Evidence grade: Low
This review reports that in laboratory and rodent studies curcumin can limit amyloid-beta neurotoxicity, prevent aggregate formation, reduce oxidative and inflammatory injury, and improve cognition and behaviour in animals. It notes limitations such as poor bioavailability, and no disease-altering treatment for Alzheimer's disease currently exists.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Panda, S., Kumar, A., Rani, S., & Bag, S. (2025). Investigating The Neuroprotective Role of Curcumin in Alzheimer's Disease Models. Journal of Pharmacology Genetics and Molecular Biology. https://doi.org/10.64062/jpgmb.vol1.issue4.13
Vancouver
Panda S, Kumar A, Rani S, Bag S. Investigating The Neuroprotective Role of Curcumin in Alzheimer's Disease Models. Journal of Pharmacology Genetics and Molecular Biology. 2025. doi:10.64062/jpgmb.vol1.issue4.13.
BibTeX
@article{panda2025-1b5cecc3,
author = {Panda, Soumyajit and Kumar, Akash and Rani, Sapna and Bag, Sowvik},
title = {{Investigating The Neuroprotective Role of Curcumin in Alzheimer's Disease Models}},
journal = {Journal of Pharmacology Genetics and Molecular Biology},
year = {2025},
doi = {10.64062/jpgmb.vol1.issue4.13},
url = {https://doi.org/10.64062/jpgmb.vol1.issue4.13}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This review provides a comprehensive study on the neuroprotective effects of curcumin in the case of Alzheimer disease, its biochemical and pharmacological profile in its application regarding unique chemical content, bioactive compounds of curcumin, and pharmacokinetic constraints, like poor bioavailability.
- In vitro studies at the preclinical level show that curcumin can limit neurotoxicity caused by amyloid beta, prevent the formation of aggregates, and limit oxidative and inflammatory injuries and in vivo-based rodent trials report both cognitive and behavioural enhancements as well as the decrease of amyloid plaque and hyperphosphorylation of tau proteins.
- However, several limitations like low bioavailability, absence of large-scale, clinical trials, and insufficiency of long range safety make clinical implementation poor.
- The future study is needed to create a nano formulation, which will improve its bioavailability and combination therapies, which will produce a synergistic neuroprotective effect.
- In general, curcumin has a large potential as effective safe multi-targeted therapy against Alzheimer disease and its relevance should be further investigated due to conducting well-conducted human trials that may determine its effectiveness.
Why it matters
This review reports that in laboratory and rodent studies curcumin can limit amyloid-beta neurotoxicity, prevent aggregate formation, reduce oxidative and inflammatory injury, and improve cognition and behaviour in animals. It notes limitations such as poor bioavailability, and no disease-altering treatment for Alzheimer's disease currently exists.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Pharmacology Genetics and Molecular Biology) |
| Journal's citation record | 0 / 4 | Journal of Pharmacology Genetics and Molecular Biology: journal h-index 2 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Maharishi Markandeshwar University, Mullana: institution h-index 154 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 27 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.64062/jpgmb.vol1.issue4.13
- Original source →
- Free full text: Journal of Pharmacology Genetics and Molecular Biology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.